BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33181752)

  • 21. Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.
    Venema CM; Apollonio G; Hospers GA; Schröder CP; Dierckx RA; de Vries EF; Glaudemans AW
    Clin Nucl Med; 2016 Nov; 41(11):844-851. PubMed ID: 27607175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
    Ulaner GA; Vaz SC
    Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
    Evangelista L; Guarneri V; Conte PF
    Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
    Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
    Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
    Peterson LM; Kurland BF; Schubert EK; Link JM; Gadi VK; Specht JM; Eary JF; Porter P; Shankar LK; Mankoff DA; Linden HM
    Mol Imaging Biol; 2014 Jun; 16(3):431-40. PubMed ID: 24170452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-
    Ulaner GA; Mankoff DA; Clark AS; Fowler AM; Linden HM; Peterson LM; Dehdashti F; Kurland BF; Mortimer J; Mouabbi J; Moon DH; de Vries EGE
    J Nucl Med; 2023 Mar; 64(3):351-354. PubMed ID: 36863779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
    Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
    Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
    Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer
    Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE
    J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
    Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
    Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
    Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
    Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
    Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
    J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[
    Katzenellenbogen JA
    Nucl Med Biol; 2021 Jan; 92():24-37. PubMed ID: 32229068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature.
    Bodapati S; Abraham P; Chen A; Guilbault D; McDonald M; Matro J; Shatsky R; Obrzut S
    Tomography; 2022 Apr; 8(2):1060-1065. PubMed ID: 35448720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
    Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
    Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-Fluoroestradiol Tumor Uptake Is Influenced by Structural Components in Breast Cancer.
    Takahashi M; Maeda H; Tsujikawa T; Kono H; Mori T; Kiyono Y; Okazawa H; Noriki S; Imamura Y; Goi T
    Clin Nucl Med; 2021 Nov; 46(11):884-889. PubMed ID: 34319950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals.
    Seimbille Y; Rousseau J; Bénard F; Morin C; Ali H; Avvakumov G; Hammond GL; van Lier JE
    Steroids; 2002 Aug; 67(9):765-75. PubMed ID: 12123788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
    Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
    Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Potential of Estrogen and Progesterone Receptor Imaging.
    Linden HM; Peterson LM; Fowler AM
    PET Clin; 2018 Jul; 13(3):415-422. PubMed ID: 30100079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.